# A Long Term Safety Study With Atrasentan

> **NCT00127478** · PHASE2,PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 166 (actual)

## Conditions studied

- Prostate Cancer
- Adenocarcinoma

## Interventions

- **DRUG:** Atrasentan

## Key facts

- **NCT ID:** NCT00127478
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2007-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00127478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00127478, "A Long Term Safety Study With Atrasentan". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00127478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*